Table 3.
Summary of thrombotic microangiopathy notifications induced by interferon beta-1a (IFNβ) from French Pharmacovigilance Database
| Year | Age | Duration of treatment | Disease | Clinical | Treatment | Laboratory investigations | Outcome |
|---|---|---|---|---|---|---|---|
| 2006 | 47 | 1 year | MS | Proteinuria | Discontinuation of IFNβ | Remission | |
| 2007 | 58 | 5 years | MS | HUS + hypertension | Discontinuation of IFNβ + plasmapheresis + steroids | Chronic kidney disease | |
| 2008 | 55 | 6 years | MS | TTP | Discontinuation of IFNβ + plasmapheresis + steroids + rituximab | IgG anti-ADAMTS 13 positive | Remission |
| 2009 | 66 | 1 year | MS | HUS + hypertension | Discontinuation of IFNβ + urapidil | Remission | |
| 2009 | 65 | 1 year | MS | Nephrotic syndrome | NA | NA | |
| 2010 | 38 | 10 years | MS | TTP | Discontinuation of IFNβ + plasmapheresis + steroids | NA | |
| 2011 | 44 | 3 years | MS | Renal failure + hypertension | Discontinuation of IFNβ + plasmapheresis | Antinuclear-antibodies positive | Chronic kidney disease |
| 2012 | 52 | >3 years | MS | HUS + hypertension | Discontinuation of IFNβ + plasmapheresis + nebivolol | Decreased activity of ADAMTS 13 | Chronic kidney disease |
Abbreviations: ADAMTS, A disintegrin and metalloproteinase with thrombospondin 1 motifs; Ig, immunoglobulin; NA, not available; HUS, hemolytic-uremic syndrome; MS, multiple sclerosis; TTP, thrombotic thrombocytopenic purpura.